Autres langues Cerenome, Inc.

Actions

CNSY

US72941H8060

Recherche biotechnologique et médicale

Temps Différé Nasdaq 16:40:49 26/08/2026			Varia. 5j.	Varia. 1 janv.
3,040 ^USD	-1,46%		-4,70%	-76,26%

14/08	Cerenome, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
03/08	Plus Therapeutics, Inc. changera son symbole boursier de PSTV à CNSY	CI

Autres langues

20/08	Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
14/08	Cerenome: Q2 Earnings Snapshot
14/08	Cerenome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
14/08	Cerenome Reports Second Quarter 2026 Financial Results and Business Update
13/08	Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
06/08	Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
03/08	Plus Therapeutics, Inc. - Cerenome Launches as an Integrated CNS Oncology Company
03/08	Plus Therapeutics, Inc. will Change its Name to Cerenome
03/08	Plus Therapeutics, Inc. will Change its Ticker to CNSY from PSTV
31/07	Cerenome Launches as an Integrated CNS Oncology Company
28/07	Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
21/07	Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
16/07	Plus Therapeutics, Inc. And Genomic Testing Cooperative, LCA Partner To Integrate Next-Generation Sequencing Into The CNSide CSF Assay Platform
16/07	Plus Therapeutics, Genomic Testing Cooperative to Integrate NGS Technology Into CNSide CSF Assay Platform
16/07	Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
14/07	Plus Therapeutics, Inc. Highlights Updated NCCN CNS Cancers Guidelines and Reinforces Clinical Role of CNSide in Leptomeningeal Metastases Monitoring
14/07	Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
30/06	Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress
30/06	Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
29/06	Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell 3000E Index
29/06	Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell 3000E Growth Benchmark
29/06	Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell Microcap Growth Benchmark Index
29/06	Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell Microcap Index
26/06	Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer
25/06	Plus Therapeutics Unit Signs Coverage Agreement With Elevance Health for CNSide Assay